Advertisement

2017 GI Cancers Symposium: Physical Activity May Be Linked to Longer Survival in Advanced Colorectal Cancer

Advertisement

Key Points

  • The patients that were most physically active engaged in 18 or more MET-hours per week, equivalent to 30 or more minutes each day of moderate physical activity, such as walking, cleaning, or gardening.
  • The group that was the least physically active engaged in less than 3 MET-hours per week, equivalent to 30 minutes of physical activity per week.
  • People who spent 5 or more hours per week engaged in nonvigorous activity had a 25% reduction in mortality.

A new analysis of the CALGB 80405 (Alliance) trial suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active. In a large clinical trial, patients who at the time of starting chemotherapy reported engaging in physical activity equivalent to 30 or more minutes of moderate exercise daily had a 19% reduction in mortality and a 16% reduction in cancer progression. The study will be presented by Guercio et al at the upcoming 2017 Gastrointestinal Cancers Symposium in San Francisco, California (Abstract 659).

According to the authors, this analysis is the first evidence of such a link in patients with colorectal cancer involving distant metastases. Prior studies have consistently shown a link between regular exercise and improved outcomes in patients with earlier-stage colorectal cancer (without distant metastases).

“These findings suggest that it doesn’t take a lot of physical activity to improve outcomes,” said lead study author Brendan John Guercio, MD, a resident physician at Brigham and Women’s Hospital. “While exercise is by no means a substitute for chemotherapy, patients can experience a wide range of benefits from as little as 30 minutes of exercise a day.”

About CALGB 80405

The analysis included 1,231 patients enrolled in the federally funded phase III CALGB 80405 trial of chemotherapy for metastatic colorectal cancer. At the time they began receiving chemotherapy, patients self-reported their physical activity through a questionnaire. Based on their responses, the researchers determined the level of physical activity for each patient using a standard measure called metabolic equivalent task (MET)-hours per week, which assesses energy expended during physical activity.

The patients that were most physically active engaged in 18 or more MET-hours per week, equivalent to 30 or more minutes each day of moderate physical activity, such as walking, cleaning, or gardening. The group that was the least physically active engaged in less than 3 MET-hours per week, equivalent to 30 minutes of physical activity per week. Researchers adjusted for factors that may affect patient ability to participate in physical activity, such as age, general health, body weight change, other chronic illnesses, and type of cancer therapy received.

Key Findings

Overall, patients who spent more time being physically active had reduced rates of cancer progression and death. In a secondary exploratory analysis, more time spent in nonvigorous physical activity, such as walking or lawn mowing, was linked to improved survival. People who spent 5 or more hours per week engaged in nonvigorous activity had a 25% reduction in mortality. However, there was no association between vigorous physical activity, such as running and playing sports, and cancer outcomes.

Next Steps

Randomized controlled trials and more prospective clinical studies are needed to confirm the associations between physical activity and outcomes in metastatic colorectal cancer. A randomized clinical trial that is currently ongoing and compares patients who exercise during treatment and those who do not might prove that physical activity leads to longer survival.

This study was supported by grants from the National Institutes for Health.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement